Skip to content

Psilocybin: a revolution in psychedelic medicines in the US?

Joanne Silberner

BMJ October 6, 2022 DOI: 10.1136/bmj.o2178 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Review Peer reviewed
Topics Psilocybin
Keywords Hallucinogen Depression economics
Citations 1
Key findings Psilocybin, the most carefully studied psychedelic drug, may revolutionize treatment of depression and other psychiatric ailments as US states approve its medicinal use.

Abstract

As a flurry of US states approve psilocybin for medicinal use, Joanne Silberner asks whether the most carefully studied of psychedelic drugs will revolutionise treatment of depression and other psychiatric ailments

Explore topics